Provided by Tiger Trade Technology Pte. Ltd.

Protagonist Therapeutics

151.50
+0.91000.60%
Post-market: 151.500.00000.00%19:30 EDT
Volume:335.46K
Turnover:50.53M
Market Cap:9.80B
PE:147.09
High:152.07
Open:150.36
Low:147.69
Close:150.59
52wk High:160.81
52wk Low:54.50
Shares:64.71M
Float Shares:63.17M
Volume Ratio:0.59
T/O Rate:0.53%
Dividend:- -
Dividend Rate:- -
EPS(TTM):1.03
EPS(LYR):-2.0500
ROE:10.98%
ROA:4.55%
PB:11.65
PE(LYR):-73.90

Loading ...

Barclays Sticks to Their Buy Rating for Protagonist Therapeutics (PTGX)

TIPRANKS
·
May 06

Analysts’ Top Healthcare Picks: Biodesix (BDSX), Protagonist Therapeutics (PTGX)

TIPRANKS
·
May 06

Protagonist Therapeutics Q1 EPS $0.05 Beats $(0.42) Estimate, Sales $56.368M Beat $16.273M Estimate

Benzinga Earnings
·
May 06

Protagonist Therapeutics Q1 revenue doubles on ICOTYDE milestone

Reuters
·
May 06

Protagonist returns to Q1 FY26 profit; revenue rises to $56.37 million

Reuters
·
May 06

BRIEF-Protagonist Therapeutics Q1 EPS USD 0.05

Reuters
·
May 06

Analysts Conflicted on These Healthcare Names: Molina Healthcare (MOH), Design Therapeutics (DSGN) and Protagonist Therapeutics (PTGX)

TIPRANKS
·
Apr 29

Protagonist Therapeutics announces annual shareholder meeting via online webcast

Reuters
·
Apr 29

Protagonist Therapeutics Opts Out of Rusfertide US Profit-Sharing Arrangement With Takeda Pharmaceutical

MT Newswires Live
·
Apr 28

Protagonist exercises right to opt out of 50:50 U.S. arrangement for rusfertide

TIPRANKS
·
Apr 28

High Growth Tech Stocks To Watch In US April 2026

Simply Wall St.
·
Apr 25

Protagonist Therapeutics Insider Move: CFO Cashes In on a Notable Stock Sale

TIPRANKS
·
Apr 22

Protagonist Therapeutics grants inducement awards for 55,425 stock options, 14,425 RSUs

Reuters
·
Apr 17

Protagonist Therapeutics Is Maintained at Buy by Truist Securities

Dow Jones
·
Apr 15

Truist Raises Price Target on Protagonist Therapeutics to $121 From $110, Keeps Buy Rating

MT Newswires Live
·
Apr 15

Protagonist Therapeutics: Icotyde’s Rapid Psoriasis Uptake and Multibillion‑Dollar Peak Sales Potential Support Buy Rating and Higher $121 Target

TIPRANKS
·
Apr 15

Protagonist Therapeutics price target raised to $121 from $110 at Truist

TIPRANKS
·
Apr 15

J&J raises guidance for 2026 on strong start to the year

Dow Jones
·
Apr 14

Protagonist Therapeutics Inc : Clear Street Raises Target Price to $116 From $104

THOMSON REUTERS
·
Apr 07

Protagonist Therapeutics Is Maintained at Buy by Clear Street

Dow Jones
·
Apr 07